Eledon Pharmaceuticals, Inc. - Common Stock, $0.001 par value (ELDN) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value
Symbol
ELDN on Nasdaq
Shares outstanding
78,914,349
Price per share
$2.21
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
43,989,694
Total reported value
$66,415,664
% of total 13F portfolios
0%
Share change
+5,000,000
Value change
-$2,708,395
Number of holders
89
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Eledon Pharmaceuticals, Inc. - Common Stock, $0.001 par value (ELDN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Coastlands Capital LP 5% -16% $6,733,682 -$1,410,519 3,937,826 -17% Coastlands Capital LP 31 Dec 2025
BlackRock, Inc. 4.6% -16% $5,474,994 +$563,100 3,625,824 +11% BlackRock, Inc. 31 Dec 2025
VANGUARD GROUP INC 5.5% $8,992,818 3,318,383 The Vanguard Group 30 Jun 2025
ARMISTICE CAPITAL, LLC 5% $10,259,798 3,137,553 Armistice Capital, LLC 31 Dec 2024
Frazier Life Sciences Public Fund, L.P. 2% $3,847,923 1,176,735 James N. Topper 31 Dec 2024

As of 31 Dec 2025, 89 institutional investors reported holding 43,989,694 shares of Eledon Pharmaceuticals, Inc. - Common Stock, $0.001 par value (ELDN). This represents 56% of the company’s total 78,914,349 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Eledon Pharmaceuticals, Inc. - Common Stock, $0.001 par value (ELDN) together control 52% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BVF INC/IL 8% 6,293,282 0% 0.32% $9,502,856
VANGUARD GROUP INC 5.1% 4,039,686 +24% 0% $6,099,926
BlackRock, Inc. 4.6% 3,627,208 +4.7% 0% $5,477,084
Defilade Capital Management, L.P. 4.2% 3,290,450 0% 0.67% $4,968,580
Ensign Peak Advisors, Inc 3.1% 2,464,919 +95% 0.01% $3,722,028
Zimmer Partners, LP 3% 2,384,228 +31% 0.09% $3,600,184
SPHERA FUNDS MANAGEMENT LTD. 2.7% 2,132,131 +67% 0.67% $3,219,518
Blue Owl Capital Holdings LP 2.4% 1,929,912 +97% 0.22% $2,914,167
ADAR1 Capital Management, LLC 2.3% 1,821,812 0.21% $2,750,936
Jefferies Financial Group Inc. 2% 1,580,625 0.02% $2,386,744
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,421,617 +3.8% 0% $2,146,964
Catalio Capital Management, LP 1.6% 1,259,820 +19% 0.36% $1,902,328
AWM Investment Company, Inc. 1.4% 1,100,000 0.16% $1,661,000
KINGDON CAPITAL MANAGEMENT, L.L.C. 1.3% 1,039,275 0.24% $1,569,305
Stonepine Capital Management, LLC 1.1% 893,100 1.1% $1,348,581
Sanofi 1% 814,980 0% 0.4% $1,230,620
STATE STREET CORP 0.98% 773,885 +18% 0% $1,168,566
CM Management, LLC 0.82% 650,000 +8.3% 0.83% $981,500
22NW, LP 0.81% 636,364 0% 0.74% $960,910
SG Americas Securities, LLC 0.8% 627,392 0% $947,000
UBS Group AG 0.75% 593,131 +535% 0% $895,628
Caligan Partners LP 0.7% 555,978 0.08% $839,527
JANE STREET GROUP, LLC 0.62% 489,376 +151% 0% $738,958
NORTHERN TRUST CORP 0.54% 429,813 +0.29% 0% $649,018
Focus Partners Wealth 0.4% 317,443 0% $479,339

Institutional Holders of Eledon Pharmaceuticals, Inc. - Common Stock, $0.001 par value (ELDN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 43,989,694 $66,415,664 -$2,708,395 $1.51 89
2025 Q3 36,469,559 $94,453,818 -$12,219,070 $2.59 82
2025 Q2 40,843,175 $110,685,079 +$5,557,133 $2.71 85
2025 Q1 38,448,901 $130,340,726 -$2,283,033 $3.39 83
2024 Q4 38,479,556 $158,542,263 +$81,995,653 $4.12 75
2024 Q3 18,485,827 $46,028,922 +$410,879 $2.49 33
2024 Q2 18,259,810 $48,206,187 +$22,892,459 $2.64 31
2024 Q1 9,595,061 $19,765,324 +$914,973 $2.06 28
2023 Q4 9,153,168 $16,475,058 +$507,102 $1.80 28
2023 Q3 8,917,722 $12,217,005 -$186,914 $1.37 28
2023 Q2 9,275,200 $12,707,758 +$2,932,975 $1.37 32
2023 Q1 6,240,661 $14,727,632 -$15,081 $2.36 29
2022 Q4 6,249,494 $14,377,182 -$299,603 $2.28 27
2022 Q3 6,267,437 $17,296,971 -$726,076 $2.76 26
2022 Q2 6,534,650 $15,944,119 -$1,242,145 $2.44 27
2022 Q1 7,004,967 $27,598,192 -$4,350,190 $3.94 30
2021 Q4 7,884,710 $34,745,775 -$3,532,209 $4.41 34
2021 Q3 8,434,281 $52,121,569 -$6,530,652 $6.18 29
2021 Q2 9,423,304 $74,527,000 +$5,445,356 $7.91 29
2021 Q1 8,317,680 $88,956,000 +$88,566,000 $10.70 32
2020 Q4 36,111 $556,000 +$556,000 $15.40 1